Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer

Sponsor
Shandong Provincial Hospital
Study ID
NCT04102982
Phase
PHASE2
Status
Unknown

Conditions

  • NSCLC Stage IV

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Patients were randomized to microwave ablation plus camrelizumab group or camrelizumab group.

Key Dates

Start date
Nov 1, 2019
Status verified
Oct 2020
Primary completion
Oct 31, 2021
Completion
Feb 28, 2022

Study Design

Enrollment
200 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER

Arms

  • Active Comparator: Microwave ablation plus camrelizumab group
    Patients in the group are treated with Microwave ablation in the primary tumor, followed by camrelizumab.
  • Placebo Comparator: Camrelizumab group
    Patients in the group are treated with camrelizumab alone.

Primary Outcome Measure

Objective response rate [ Time Frame: The proportion of Patients achieved complete response or partial response up to 16 weeks ]

Central Contacts

Related Studies